Know Cancer

or
forgot password

Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)


N/A
18 Years
N/A
Not Enrolling
Both
Leukoplakia, Hairy, HIV Infections

Thank you

Trial Information

Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)

Inclusion Criteria


Inclusion Criteria

Concurrent Medication:

Allowed:

- Topical antifungal therapy.

Patient must have:

- Newly diagnosed clinical and histological hairy leukoplakia.

- Positive HIV antibody by licensed ELISA or Western blot.

Exclusion Criteria

Co-existing Condition:

Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded.

Concurrent Medication:

Excluded within 2 weeks of study entry:

- Systemic antifungal treatment.

- Excluded within 6 weeks of study entry:

- Immunomodulators.

- Systemic antiviral treatment.

Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded.

Prior Medication:

Excluded within 2 weeks of study entry:

- Systemic antifungal.

- Excluded within 6 weeks of study entry:

- Immunomodulators.

- Systemic antiviral treatment.

- Excluded within 8 weeks of study entry:

- Zidovudine (AZT) or other antiretroviral therapy.

Type of Study:

Interventional

Study Design:

Primary Purpose: Treatment

Authority:

United States: Food and Drug Administration

Study ID:

033A

NCT ID:

NCT00002026

Start Date:

Completion Date:

Related Keywords:

  • Leukoplakia, Hairy
  • HIV Infections
  • AIDS-Related Opportunistic Infections
  • Leukoplakia, Oral
  • Herpesvirus 4, Human
  • Acyclovir
  • AIDS-Related Complex
  • HIV Infections
  • Acquired Immunodeficiency Syndrome
  • Leukoplakia
  • Leukoplakia, Hairy

Name

Location

Univ of Southern California / LA County USC Med CtrLos Angeles, California  900331079